PRKDC and Miyoshi myopathy: Additional targeting of NHEJ using a DNA–PK inhibitor, NU7026, augmented the cytotoxicity of the melphalan/veliparib combination in drug resistant MM cell lines and cell line xenografts (143), suggesting that dual DDR inhibitor combinations may also be attractive options for evaluation in clinical trials.